The highly anticipated Retatrutide 20mg device, a novel dual GIP and GLP-1 target , is currently under review by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. General access remains https://buyretatrutideweightloss.co.uk/product/glow-70mg-peptide-uk/